Rozanolixizumab Maintains Efficacy Among Generalized Myasthenia Gravis Subgroups
PHOENIX – Across subgroups, patients who had their generalized myasthenia gravis (gMG) treated with rozanolixizumab (Rystiggo) maintained their responses through multiples cycles of treatment, based on extension data from the phase III MycarinG clinical trial. Those with anti-acetylcholine receptor (AChR)-positive gMG receiving the higher dose of rozanolixizumab saw average Myasthenia Gravis-Activities of Daily Living (MG-ADL) […]
FDA Greenlights New Myasthenia Gravis Drug
The FDA approved rozanolixizumab-noli (Rystiggo), a neonatal Fc receptor blocker, to treat adults with generalized myasthenia gravis (gMG), UCB announced Tuesday. The drug is the first approved to treat both of the two most common subtypes of gMG patients — those who are anti-acetylcholine receptor (AChR)-positive and those who are anti-muscle-specific tyrosine kinase (MuSK) antibody-positive. […]